**Supplemental Digital Content 6: Sensitivity analysis of serum C4 level of the HC and NAFLD groups using the analysis of covariance model with BMI and HOMA-IR as covariates**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | P-value |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | HC | HC | MF |
| Serum C4(μM) | HC |  | NAFLD (MF) |  |  | NAFLD (AF) |  | vs | vs | vs |
| (n = 55) | 　 | 　 | (n = 52) | 　 | 　 | (n = 34) | 　 | AF | MF | AF |
|  C4 | 1.5  | ( | 0.8  | - | 2.2  | ) | 　 | 2.9  | ( | 2.3  | - | 3.5  | ) | 　 | 3.8  | ( | 3.1  | - | 4.6  | ) | 0.0003 | 0.02 | 0.08 |

Data are presented as mean ± 95% Confidence Interval.

AF, advanced fibrosis; BA, bile acid; BMI, body mass index; C4, 7α-hydroxy-4-cholesten-3-one; HC, healthy control; HOMA-IR, homeostasis model assessment of insulin resistance; MF, mild fibrosis; NAFLD, nonalcoholic fatty liver disease.